| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Decade of Never-smokers Among Lung Cancer Patients—Increasing Trend and Improved Survival
|
Toh, Chee-Keong
|
|
2018
|
19 |
5 |
p. e539-e550
|
article
|
| 2 |
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines
|
Ren, Shengxiang
|
|
2018
|
19 |
5 |
p. 450-456
|
article
|
| 3 |
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
|
Fujimoto, Nobukazu
|
|
2018
|
19 |
5 |
p. e705-e707
|
article
|
| 4 |
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer and Systemic Inflammation
|
Giaccone, Giuseppe
|
|
2018
|
19 |
5 |
p. e567-e574
|
article
|
| 5 |
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol
|
Kogure, Yoshihito
|
|
2018
|
19 |
5 |
p. e711-e715
|
article
|
| 6 |
Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer
|
Saiki, Masafumi
|
|
2018
|
19 |
5 |
p. 435-440.e1
|
article
|
| 7 |
Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)
|
Atagi, Shinji
|
|
2018
|
19 |
5 |
p. e619-e627
|
article
|
| 8 |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
|
Oh, In-Jae
|
|
2018
|
19 |
5 |
p. e775-e781
|
article
|
| 9 |
Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia
|
Loong, Herbert H.
|
|
2018
|
19 |
5 |
p. e601-e608
|
article
|
| 10 |
Clinical Characteristics and Prognosis of Patients With Advanced Non–Small-cell Lung Cancer Who Are Ineligible for Clinical Trials
|
Kawachi, Hayato
|
|
2018
|
19 |
5 |
p. e721-e734
|
article
|
| 11 |
Comparing Outcomes of Patients With Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status
|
Raghavan, Govind
|
|
2018
|
19 |
5 |
p. e759-e766
|
article
|
| 12 |
Comparing Treatment Strategies for Stage I Small-cell lung Cancer
|
Paximadis, Peter
|
|
2018
|
19 |
5 |
p. e559-e565
|
article
|
| 13 |
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non–Small-Cell Lung Cancer
|
Zer, Alona
|
|
2018
|
19 |
5 |
p. 426-434.e1
|
article
|
| 14 |
Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes
|
Zhang, Chaoyang
|
|
2018
|
19 |
5 |
p. e675-e683
|
article
|
| 15 |
Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma
|
Taus, Álvaro
|
|
2018
|
19 |
5 |
p. 387-394.e2
|
article
|
| 16 |
Editorial Board
|
|
|
2018
|
19 |
5 |
p. A6
|
article
|
| 17 |
Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non–Small-cell Lung Cancer
|
Ginestet, Florent
|
|
2018
|
19 |
5 |
p. e647-e653
|
article
|
| 18 |
Factors Associated With Treatment of Clinical Stage I Non–Small-cell Lung Cancer: A Population-based Analysis
|
Berry, Mark F.
|
|
2018
|
19 |
5 |
p. e745-e758
|
article
|
| 19 |
Incidental Pulmonary Malignancies on CTAC in MPS
|
Delaney, Francis T.
|
|
2018
|
19 |
5 |
p. e801-e802
|
article
|
| 20 |
Lung Cancers Detected on Computed Tomography Attenuation Correction Images During Myocardial Perfusion Scintigraphy
|
Tamura, Tomohiro
|
|
2018
|
19 |
5 |
p. e709
|
article
|
| 21 |
Molecular Testing Turnaround Time in Non–Small-Cell Lung Cancer: Monitoring a Moving Target
|
VanderLaan, Paul A.
|
|
2018
|
19 |
5 |
p. e589-e590
|
article
|
| 22 |
Nivolumab-induced Limbic Encephalitis with Anti-Hu Antibody in a Patient With Advanced Pleomorphic Carcinoma of the Lung
|
Matsuoka, Hiroki
|
|
2018
|
19 |
5 |
p. e597-e599
|
article
|
| 23 |
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer
|
Bordoni, Rodolfo
|
|
2018
|
19 |
5 |
p. 441-449.e4
|
article
|
| 24 |
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors
|
Camidge, D. Ross
|
|
2018
|
19 |
5 |
p. e655-e665
|
article
|
| 25 |
Primary Thoracic Cancers Incidentally Detected on CT Attenuation Correction Images During Myocardial Perfusion Scintigraphy
|
Delaney, Francis T.
|
|
2018
|
19 |
5 |
p. e575-e579
|
article
|
| 26 |
Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer
|
Chin, Alexander L.
|
|
2018
|
19 |
5 |
p. e581-e588
|
article
|
| 27 |
Programmed Cell Death Ligand 1 Expression in Non–Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study
|
Fujimoto, Daichi
|
|
2018
|
19 |
5 |
p. e667-e673
|
article
|
| 28 |
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non–Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin
|
Hirsh, Vera
|
|
2018
|
19 |
5 |
p. 401-409.e4
|
article
|
| 29 |
Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non–small-cell Lung Cancer (NCT02788461)
|
Raman, Srinivas
|
|
2018
|
19 |
5 |
p. e699-e703
|
article
|
| 30 |
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study
|
Bittoni, Marisa A.
|
|
2018
|
19 |
5 |
p. e629-e645
|
article
|
| 31 |
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer
|
Arunachalam, Ashwini
|
|
2018
|
19 |
5 |
p. e783-e799
|
article
|
| 32 |
Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature
|
Vittorio, Alexander
|
|
2018
|
19 |
5 |
p. e717-e720
|
article
|
| 33 |
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
|
Imbimbo, Martina
|
|
2018
|
19 |
5 |
p. e811-e814
|
article
|
| 34 |
Risk Factors of Recurrence in Patients With Clinical Stage IA Adenocarcinoma Presented as Ground-Glass Nodule
|
Su, Hang
|
|
2018
|
19 |
5 |
p. e609-e617
|
article
|
| 35 |
ROS1-Rearranged Non–Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses
|
Lee, Adrian
|
|
2018
|
19 |
5 |
p. 457-459
|
article
|
| 36 |
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community
|
Su, Christopher T.
|
|
2018
|
19 |
5 |
p. e767-e773
|
article
|
| 37 |
Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis
|
Toyokawa, Gouji
|
|
2018
|
19 |
5 |
p. 395-400.e1
|
article
|
| 38 |
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
|
Okuma, Yusuke
|
|
2018
|
19 |
5 |
p. 410-417.e1
|
article
|
| 39 |
Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis
|
Andersson, Saana
|
|
2018
|
19 |
5 |
p. 418-425
|
article
|
| 40 |
Table of Contents
|
|
|
2018
|
19 |
5 |
p. A7-A9, A15-A19
|
article
|
| 41 |
Toward a Molecular Diagnosis in a Single Day for Patients With Advanced Non–small-cell Lung Cancer
|
Lambros, Laetitia
|
|
2018
|
19 |
5 |
p. e537-e538
|
article
|
| 42 |
Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group
|
Rodríguez de Dios, Nuria
|
|
2018
|
19 |
5 |
p. e693-e697
|
article
|
| 43 |
Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma
|
Gong, Zhihua
|
|
2018
|
19 |
5 |
p. e551-e558
|
article
|
| 44 |
Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience
|
Raman, Srinivas
|
|
2018
|
19 |
5 |
p. e803-e810
|
article
|
| 45 |
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy
|
Shukla, Navika D.
|
|
2018
|
19 |
5 |
p. 377-386
|
article
|
| 46 |
Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States
|
Shaaban, Sherif G.
|
|
2018
|
19 |
5 |
p. e685-e692
|
article
|
| 47 |
Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non–Small-cell Lung Cancer: Clinical and Budget Effect
|
Paolini, Davide
|
|
2018
|
19 |
5 |
p. e735-e743
|
article
|
| 48 |
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient
|
Facchinetti, Francesco
|
|
2018
|
19 |
5 |
p. e591-e596
|
article
|
Journal description